Research Update End-Year-1 CHF-02489: Collagen Signatures in Canine Mammary Gland Tumors: Development of Prognostic Markers and Targeted Therapies for Improved Outcomes

Research Update from Dr. Volk for improving outcomes of mammary gland tumor treatment with targeted therapies.

Mammary gland tumors (MGT) are the most common malignancies in intact female dogs and recent work indicates that normal, non-malignant cells and extracellular matrix (ECM) within the surrounding tumor stroma regulates the growth and spread of cancer. Our recent study has identified cancerassociated collagen signatures in canine MGT biopsy samples that predict clinical outcome better than commonly used markers. Also, our labs have shown that inhibition of a collagen degrading enzyme (Fibroblast Activation Protein (FAP)) and increasing a tumor-suppressive collagen (type III collagen (Col3)) prevents the formation of these tumor-inciting signatures in other species (mouse and human).

Building on these results, we have recently used a novel imaging technique to look at collagen types in MGT samples. Our data suggests that type of collagen as well as the amount and type of collagen cross-linking in tumor samples may be useful in predicting clinical outcome of patients. Based on our published and new data, we predict that identifying and targeting tumor-inciting collagen signatures will improve both diagnosis and treatment of dogs with malignant MGT

End-Year-1 Research Update Dr. Volk for improved treatment of mammary tumors with targeted therapies.